FDA Approves Genzyme's Cerdelga (eliglustat) capsules

Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that the U.S. Food and Drug Administration (FDA) has approved Cerdelga™ (eliglustat) capsules, the only first-line oral therapy for certain adult Gaucher disease type 1 patients. A small number of adult patients who metabolize Cerdelga more quickly or at an undetermined rate, as detected by an established genetic laboratory test, will not be eligible for Cerdelga treatment. Cerdelga is expected to be available to patients within a month. Click below to read full press release.

http://news.genzyme.com/press-release/fda-approves-genzymes-cerdelga-eliglustat-capsules